Chap 25: Heart Failure/ Pulmonary edema: Flashcards
Heart Failure (HF)
- A clinical syndrome resulting from structural or functional cardiac disorders that impair the ability of the ventricles to fill or eject blood
- In the past, HF was often referred to as congestive heart failure (CHF), because many patients experience pulmonary or peripheral congestion with edema
- HF is recognized as a clinical syndrome characterized by signs and symptoms of fluid overload or inadequate tissue perfusion
- The term heart failure indicates myocardial disease, in which there is a problem with the contraction of the heart (systolic failure) or filling of the heart (diastolic failure)
- Some cases are reversible depending on the cause
- Most HF is a chronic, progressive condition managed with lifestyle changes and medications
- Fluid overload and decreased tissue perfusion result when the heart cannot generate cardiac output (CO) sufficient to meet the body’s demands for oxygen and nutrients.
- Heart failure is the inability of the heart to maintain adequate cardiac output to meet the metabolic needs of the body because of the impaired pumping ability.
- *Diminished cardiac output results in inadequate peripheral tissue perfusion
- *Congestion of the lungs and periphery may occur; the client can develop acute pulmonary edema
Chronic V. Acute HF
- Acute heart failure occurs suddenly
- Chronic heart failure develops over time. A person with chronic heart failure can and does develop an acute episode.
ECHOCARDIOGRAM
An assessment of the ejection fraction (EF) is performed by echocardiogram to assist in determining the type of HF.
Ejection fraction:
- EF is calculated by subtracting the amount of blood present in the left ventricle at the end of systole from the amount present at the end of diastole and calculating the percentage of blood that is ejected.
- A normal EF is 55% to 65% of the ventricular volume; the ventricle does not completely empty between contractions
Pathophysiology of Heart Failure
- Myocardial dysfunction and HF can be caused by a number of conditions, including:
— coronary artery disease
— hypertension
— cardiomyopathy
— valvular disorders
— renal dysfunction with volume overload. - Patients with diabetes are also at high risk for HF.
- Atherosclerosis of the coronary arteries is a primary cause of HF, and coronary artery disease is found in the majority of patients with HF.
- Ischemia causes myocardial dysfunction because it deprives heart cells of oxygen and causes cellular damage.
- MI causes focal heart muscle necrosis, the death of myocardial cells, and a loss of contractility; the extent of the infarction correlates with the severity of HF.
- Revascularization of the coronary artery may improve myocardial oxygenation and ventricular function and prevent more extensive myocardial necrosis that can lead to HF.
— percutaneous coronary intervention (PCI)
— coronary artery bypass surgery (coronary artery bypass graft [CABG]) - Systemic or pulmonary hypertension increases afterload (resistance to ejection), which increases cardiac workload and leads to hypertrophy of myocardial muscle fibers.
— This can be considered a compensatory mechanism because it initially increases contractility. However, sustained hypertension eventually leads to changes that impair the heart’s ability to fill properly during diastole, and the hypertrophied ventricles may dilate and fail
Right ventricular failure:
right-sided heart failure (right ventricular failure): inability of the right ventricle to fill or eject sufficient blood into the pulmonary circulation
Left ventricular failure:
- left-sided heart failure (left ventricular failure): inability of the left ventricle to fill or eject sufficient blood into the systemic circulation
- Majority of heart failure begins with left ventricular failure and progresses to failure of both ventricles.
Forward failure
is an inadequate output of the affected ventricle causes decreased perfusion to vital organs
Diastolic heart failure:
the inability of the heart to pump sufficiently because of an alteration in the ability of the heart to fill; term used to describe a type of heart failure
Systolic heart failure:
- inability of the heart to pump sufficiently because of an alteration in the ability of the heart to contract; term used to describe a type of heart failure
- ACE inhibitors play a pivotal role in the management of systolic HF.
Backward failure
blood backs up behind the affected ventricle, causing increased pressure in the atrium behind the affected ventricle.
Right Sided HF
Clinical Manifestations
- Viscera and peripheral congestion
- Jugular venous distention (JVD)
- Dependent edema (legs & sacrum)
- Ascites/ abdominal distention
- Weight gain/ Increased BP
— (From fluid volume excess) - Or decreased BP (pump failure)
- Nocturnal diuresis
- Swelling of the fingers & hands
- Hepatomegaly
- Spleenomegaly
- Anorexia & nausea
Left Sided HF
Clinical Manifestations
- Pulmonary congestion, crackles
- Dry, hacking, nonproductive cough initially
- Dyspnea on exertion (DOE)
- Tachypnea
- Paroxysmal nocturnal dyspnea
- Low O2 sat
- S3 or “ventricular gallop”
- Oliguria
Pharmacologic Therapy for Heart Failure
- Several medications are routinely prescribed for HF, including ACE inhibitors, beta-blockers, and diuretics (see Table 29-3).
— ACE inhibitors and beta-blockers, improve symptoms and extend survival.
— diuretics, improve symptoms but may not affect survival.
HF meds
Classes
- Angiotensin-converting enzyme (ACE) inhibitors:
- Angiotensin II receptor blockers: ARBs
- Hydralazine and isosorbide dinitrate:
- Beta-blockers:
- Diuretics
- Digitalis
Angiotensin-converting enzyme (ACE) inhibitors:
Suffix
Suffix: -pril
- lisinopril (Prinivil)
— Relieve signs and symptoms of HF
— improve exercise tolerance
— decrease the number of hospitalizations
- Enalapril:
— Prevent progression of HF
Angiotensin-converting enzyme (ACE) inhibitors:
MOA
- ACE inhibitors block the conversion of angiotensin I to angiotensin II
- Promote vasodilation decreases afterload and preload;
— Vasodilation reduces resistance to left ventricular ejection of blood, diminishing the heart’s workload and improving ventricular emptying. - Promote diuresis (urination)
— Decrease the secretion of aldosterone, a hormone that causes the kidneys to retain sodium and water.
reducing left ventricular filling pressure and decreasing pulmonary congestion.
Angiotensin-converting enzyme (ACE) inhibitors:
S/S:
- hypotension
- *hyperkalemia
— ACE inhibitors cause the kidneys to retain potassium
— Patients who are receiving a diuretic may *not need to take oral potassium supplements.
— Patients receiving potassium-sparing diuretics (spironolactone) must be carefully monitored for hyperkalemia.
— ACE inhibitors may be discontinued if the potassium level remains greater than 5.5 mEq/L or if the serum creatinine rises. - *dry, persistent cough
— may not respond to cough suppressants. - Altered renal function (especially if they are also receiving diuretics)
- Allergic reaction accompanied by *angioedema.
— angioedema affects the oropharyngeal area and impairs breathing, the ACE inhibitor must be stopped immediately and emergency care provided. - If the patient cannot continue taking an ACE inhibitor because of development of cough, an elevated creatinine level, or hyperkalemia, pt may take:
— an angiotensin receptor blocker (ARB)
— Or a combination of hydralazine and isosorbide dinitrate (see Table 25-3)
Angiotensin-converting enzyme (ACE) inhibitors:
Indication
- First medication prescribed for patients in mild failure
patients with fatigue or DOE but without signs of fluid overload and pulmonary congestion.
— Prevention of HF in patients at risk due to vascular disease and diabetes - Severe Hyperkalemia: iv insulin
Angiotensin-converting enzyme (ACE) inhibitors:
Dose
- Started at a low dose that is gradually increased
- The final maintenance dose depends on the patient’s blood pressure, fluid status, and renal status, as well as the severity of the HF.
Angiotensin II receptor blockers: ARBs
Suffix
Suffix: -sartan
- valsartan (Diovan)
— Relieves signs and symptoms of HF
- Losartan
— Prevents progression of HF
Angiotensin II receptor blockers: ARBs
Indication
- prescribed as an alternative to ACE inhibitors; work similarly/ have similar hemodynamic effects and side effects
Angiotensin II receptor blockers: ARBs
MOA
- ARBs block the vasoconstricting effects of angiotensin II at the angiotensin II receptors.
- Lowers blood pressure and protects renal function, but it increases the risk for hyperkalemia as well as hypotension.
Angiotensin II receptor blockers: ARBs
S/S:
- Hypotention
- Hyperkalemia
- Worsening of renal function
- Angioedema is a serious adverse effect.
Hydralazine and isosorbide dinitrate:
Indication
- A combination of hydralazine and isosorbide dinitrate is an alternative for patients who cannot take ACE inhibitors.
- recommended in HF guidelines and may be more effective for African Americans who do not respond to ACE inhibitors
Nitrates:
MOA
isosorbide dinitrate
- MOA:
— cause venous dilation, which reduces the amount of blood return to the heart and lowers preload.
Hydralazine
MOA
lowers systemic vascular resistance and left ventricular afterload.
Beta-blockers:
Meds
- carvedilol (Coreg)
- bisoprolol (Zebeta)
- sustained-release metoprolol (Toprol XL)
Beta-blockers:
Indication
- prescribed in addition to ACE inhibitors; may be several weeks before effects seen (several weeks or even months)
- recommended for patients with asymptomatic systolic dysfunction, such as those with a decreased EF, to prevent the onset of symptoms of HF.
Beta-blockers:
MOA
- Block the adverse effects of the sympathetic nervous system.
- Relax blood vessels, lower blood pressure, decrease afterload, and decrease cardiac workload.